EXTON, Pa., Aug. 23 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. today announced that it completed its previously announced registered direct offering of approximately 6.76 million shares of common stock at a price of $2.04 per share to institutional investors for gross proceeds of approximately $13.8 million. The shares were offered under an effective shelf registration statement previously filed with the Securities and Exchange Commission.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Isolagen, Inc.
Isolagen(TM), Inc. is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company’s technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit www.isolagen.com.
Isolagen(TM), Inc.
CONTACT: Media, Mike Beyer of Sam Brown Inc., +1-773-463-4211,beyer@sambrown.com, for Isolagen, Inc.; Investors, Charles Huiner ofIsolagen, Inc., +1-484-713-6200, chuiner@isolagen.com
Web site: http://www.isolagen.com/
